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Abstract
Although recent preclinical and clinical studies have demonstrated that recombinant human relaxin (rhRLX) may have important therapeutic
potential in acute heart failure and chronic kidney diseases, the effects of acute rhRLX administration against renal ischaemia/reperfusion (I/R)
injury have never been investigated. Using a rat model of 1-hr bilateral renal artery occlusion followed by 6-hr reperfusion, we investigated the
effects of rhRLX (5 lg/Kg i.v.) given both at the beginning and after 3 hrs of reperfusion. Acute rhRLX administration attenuated the functional
renal injury (increase in serum urea and creatinine), glomerular dysfunction (decrease in creatinine clearance) and tubular dysfunction (increase
in urinary excretion of N-acetyl-b-glucosaminidase) evoked by renal I/R. These beneficial effects were accompanied by a significant reduction in
local lipid peroxidation, free radical-induced DNA damage and increase in the expression/activity of the endogenous antioxidant enzymes Mn-
and CuZn-superoxide dismutases (SOD). Furthermore, rhRLX administration attenuated the increase in leucocyte activation, as suggested by
inhibition of myeloperoxidase activity, intercellular-adhesion-molecule-1 expression, interleukin (IL)-1b, IL-18 and tumour necrosis factor-a
production as well as increase in IL-10 production. Interestingly, the reduced oxidative stress status and neutrophil activation here reported
were associated with rhRLX-induced activation of endothelial nitric oxide synthase and up-regulation of inducible nitric oxide synthase, possibly
secondary to activation of Akt and the extracellular signal-regulated protein kinase (ERK) 1/2, respectively. Thus, we report herein that rhRLX
protects the kidney against I/R injury by a mechanism that involves changes in nitric oxide signalling pathway.
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Introduction
Since its discovery in 1926, relaxin (RLX) has long been regarded as
a peptide hormone of ovarian origin involved in the peri-partum wid-
ening of the pubic symphysis. Subsequently, growing evidence has
suggested that RLX may exert a broad range of biological effects on
many organs and apparatuses, especially the cardiovascular system
[1]. In animal models, RLX has been reported to increase blood per-
fusion and reduce myocardial, cerebral, intestinal and pulmonary is-
chaemic damage [2–6]. In humans, clinical trials studying
intravenous recombinant human RLX (rhRLX) as a treatment for
patients hospitalized with acute heart failure have recently shown sig-
nificant improvement in clinical outcome without any major adverse
events [7, 8]. The effects of rhRLX treatment on placental blood flow,
maternal blood pressure and renal function are also being evaluated
in women with preeclampsia, a condition of new-onset hypertension
and proteinuria during pregnancy [9, 10].
The specific mechanisms by which RLX mediates its cardiovascu-
lar effects have still to be fully understood, but are key to identifying
novel targets that may be used to enhance its therapeutic potential.
Relaxin is a member of the relaxin peptide family, which, in humans,
encompasses H1, H2 and H3 RLXs as well as insulin like peptides
(INSL) 3, 5 and 6. The main circulating isoform is H2, equivalent to
other species’ relaxin-1, commonly referred to as RLX. Relaxin family
peptides target specific G-protein-coupled receptors, defined relaxin
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family peptide receptors (RXFP), of which RXFP1 is currently consid-
ered the main and specific H2 RLX receptor [11]. Recently, both RLX
peptide and its receptor RXFP1 have been identified in the renal
medulla and cortex, thus suggesting that the kidney is both a potential
source and a target organ for RLX activity [12]. Exogenous RLX
administration has been reported to reduce the progression of dis-
eases in several experimental models of renal fibrosis and the
absence of endogenous RLX may contribute to the development of
spontaneous fibrosis [13]. In addition to its well-documented antifib-
rotic actions, RLX has been shown to increase renal plasma flow and
glomerular filtration rate, attenuate the renal circulatory response to
angiotensin II and reduce plasma osmolality [14]. Although various
effects of RLX in renal diseases have been discovered, the potential
role of RLX in renal ischaemia/reperfusion injury (I/R), one of the
most common causes of acute kidney injury (AKI), has not yet been
investigated. Acute kidney injury is a major kidney disease associated
with high mortality and morbidity and several large epidemiological
studies have linked AKI with the later development of chronic and
end-stage kidney diseases [15]. Unfortunately, pharmacological inter-
ventions are limited and there is currently no successful therapy,
except for supportive care. Thus, this study was designed (i) to inves-
tigate the effects of rhRLX-2 on renal dysfunction and injury evoked
by I/R in the rat and (ii) to better elucidate the signalling mechanism
(s) by which RLX exerts its effects on the kidney.
Materials and methods
Animals and surgery
Male Wistar rats (Harlan-Italy; Udine, Italy) were fed a Piccioni pellet
diet (n.48, Gessate Milanese, Italy) and water ad libitum. Animal care
was in compliance with Italian regulations on the protection of animals
used for experimental and other scientific purposes (D.M. 116/92). The
experimental protocol, approved by the Turin University Ethics Commit-
tee, was employed in multiple previous reports from our laboratory. The
renal I/R protocol here described has been approved by the Turin Uni-
versity Ethics Committee and it was employed in multiple previous
reports from our laboratory, resulting in significant reproducible and
severe (but not fatal) renal dysfunction and injury, against which differ-
ent interventions have shown beneficial effects [16–18]. Briefly, the rats
were anaesthetized through i.p. injection (30 mg/kg) of Zoletil (15 mg/
kg tiletamine + 15 mg/kg zolazepam; Zoletil 100, 100 mg/ml, Labora-
toires Virbac, Carros Cedex, France). The anaesthetized rats were placed
onto a thermostatically controlled heating pad, a rectal temperature
probe was inserted and body temperature was monitored and main-
tained at 37°C. A midline laparotomy was performed and the bladder
was cannulated for the collection of urine. The kidneys were located
and the renal pedicles, containing the renal artery, vein, and nerves,
were carefully isolated. The rats were subjected to bilateral renal occlu-
sion for 60 min. using non-traumatic artery clamps (Dieffenbach Bull-
dog Clamps, Harvard Apparatus Ltd., Kent, United Kingdom) to clamp
the renal pedicles, followed by reperfusion for 6 hrs. Sham-operated
rats underwent identical surgical procedures to those undergoing I/R
except that artery clamps were not applied. At the end of the reperfu-
sion, the anaesthetized rats were killed by decapitation after aortic
exsanguination. The kidneys were isolated, weighed, rapidly freeze-
clamped with liquid nitrogen and stored at 80°C until needed.
Drugs and treatments
Recombinant human H2 RLX was dissolved in PBS (PBS) and adminis-
tered at the dose of 5 lg/kg (i.v) at the beginning of reperfusion and
again after 3 hrs of reperfusion. Serum concentration-time profile after
iv bolus administration of rhRLX to rats has been described by three
exponential terms, with t1/2a, t1/2b, and t1/2c in the range 1–3, 15–17,
60–70 min., respectively [19]. In humans, the half-life of RLX has been
assessed to be about 5–15 min. [20]. Besides, RLX plasma levels have
been reported to be above 40 pg/ml when measured at 18 hrs after a
single subcutaneous injection of 2 lg RLX in mice [21]. The dose of
rhRLX used was based on what we have previously shown to reduce
infarct size in an in vivo model of acute myocardial infarction [3].
Animals were randomly assigned to the following experimental groups:
● Sham: rats were treated with the vehicle (PBS, n = 8) and subjected
to the surgical procedure alone, without causing ischaemia;
● Sham + RLX: rats were treated with rhRLX (5 lg/kg i.v.) prior to the
sham operation (n = 8);
● IR: rats were subjected to 1 hr ischaemia followed by 6 hrs of reperfu-
sion and treated with the vehicle (PBS), at the beginning of reperfusion
and again after 3 hrs of reperfusion (n = 8);
● IR + RLX: rats were subjected to 1 hr ischaemia followed by 6 hrs
of reperfusion and treated with rhRLX (5 lg/kg i.v.), at the beginning
of reperfusion and again after 3 hrs of reperfusion (n = 8).
Measurement of biochemical parameters
At the end of the reperfusion period, 1 ml blood samples were collected
and centrifuged (10,000 9 g for 10 min.) to separate the serum, from
which biochemical parameters were measured within 24 hrs. The vol-
ume of urine produced was determined using the urine collected during
the reperfusion period. Serum and urine creatinine concentrations were
measured spectrophotometrically at 490 nm by the Jaffe kinetic reac-
tion, using commercially available kits. Renal creatinine clearance was
calculated by the standard formula C = (U 9 V)/P, where U is the con-
centration in urine, V is urine flow rate and P is the plasma concentra-
tion. Serum urea and creatinine concentrations and creatinine clearance
were used as indicators of impaired renal function. N-acetyl-b-glucosa-
minidase (NAG) was measured in the urine of experimental rats by a
colorimetric assay (Roche Diagnostics, Mannheim, Germany) and was
used as marker of tubular injury [22].
Histopathological examination and tissue injury
scoring
Histopathological analysis was carried out on whole kidney cryostat cross-
sections stained with either haematoxylin-eosin or Periodic acid-Schiff (PAS)
staining for glycoproteins. The used severity scoring criteria are reported in
Table 1. Each animal was assigned a separate score for glomeruli, tubuli and
blood vessel injury, evaluated by two independent observers (D.B. & A.P.)
blinded to the experimental groups, and the values were then averaged.
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Determination of thiobarbituric acid-reactive
substances
Thiobarbituric acid-reactive substances (TBARS) are end-products of cell
membrane lipid peroxidation by reactive oxygen species (ROS) and are
considered a reliable marker of oxidative stress-induced cell damage.
Thiobarbituric acid-reactive substances were determined by measure-
ment of the chromogen obtained from the reaction of malondialdehyde
with 2-thiobarbituric acid according to Aruoma et al. [23].
Determination of 8-Hydroxy-2′-deoxyGuanosine
DNA isolation from cardiac tissue homogenates was performed according
to Masini et al. [4]. Samples of DNA extract were used for 8-Hydroxy-2′-
deoxyGuanosine (8-OHdG) determination with a Bioxytech enzyme immu-
noassay kit (Oxis, Portland, OR, USA), following the instructions provided
by the manufacturer. The values are expressed as ng 8-OHdG/lg proteins.
Measurement of Mn- and CuZn-superoxide
dismutase activities
Kidney samples were homogenized with 10 mM PBS, pH 7.4, sonicated
on ice (three times, 20 sec.) and centrifuged at 100 9 g for 10 min.
Superoxide dismutases (SOD) activity was measured in the superna-
tants as described by Nishida et al. [24], with minor modifications. The
assay is based on the inhibition of nitroblue tetrazolium conversion by
SOD into a blue tetrazolium salt, mediated by superoxide radicals, which
are generated by xanthine oxidase. The amount required to inhibit the
rate of reduction of nitro blue tetrazolium by 50% was defined as one
unit of enzyme activity. Total SOD activity was determined by monitor-
ing the rate of reduction of nitroblue tetrazolium. Activity of MnSOD
was measured in the presence of 5 mM sodium cyanide and activity of
CuZnSOD was calculated by subtracting MnSOD activity from total SOD
activity.
Myeloperoxidase activity
Myeloperoxidase activity, used as an indicator of leucocyte accumula-
tion into the kidney, was determined as previously described [17].
Briefly, samples were homogenized and centrifuged for 30 min. at
13,000 9 g at 4°C. An aliquot of the supernatant was then allowed to
react with a solution of 1.6 mM tetramethylbenzidine and 0.1 mM H2O2.
The rate of change in absorbance was measured spectrophotometrically
at 460 nm. Myeloperoxidase activity was defined as the quantity of
enzyme degrading 1 lmol of peroxide/min. at 37°C and was expressed
in milliunits/g of wet tissue.
Determination of interleukin (IL)-1b, IL.18,
tumour necrosis factor (TNF)-a and IL-10
production
Cytokines were measured with commercial ELISA kits (Cayman Chemical,
Ann Arbor, MI, USA), following the protocol provided by the manufacturer.
Western blot analysis
Western blots were carried out as previously described [25]. Proteins were
separated by 8% sodium dodecyl sulphate-polyacrylamide gel electropho-
resis and transferred to polyvinyldenedifluoride membrane, which was then
incubated with primary antibodies (goat anti-ICAM-1, mouse anti-phERK,
rabbit anti-ERK, rabbit anti-iNOS, mouse anti-phAkt, rabbit anti Akt, goat
anti-ph-eNOS, rabbit anti-eNOS, goat anti-CuZnSOD, rabbit anti-MnSOD).
Blots were then incubated with a secondary antibody conjugated with
horseradish peroxidase (dilution 1:10,000) and developed with the
enhanced chemiluminescence (ECL) detection system. The immunoreac-
tive bands were visualized by autoradiography and the density of the bands
was evaluated densitometrically using Gel ProAnalyzer 4.5, 2000 software
(Media Cybernetics, Silver Spring, MD, USA). The membranes were
stripped and incubated with b-actin monoclonal antibody (dilution 1:5000)
and subsequently with an anti-mouse antibody (dilution 1:10,000) to
assess gel-loading homogeneity.
Materials
Unless otherwise stated, all compounds were purchased from the
Sigma-Aldrich Company Ltd. (St Louis, MO, USA). Clinical grade human
recombinant H2 RLX was kindly provided by Prof. Mario Bigazzi
(Foundation for the Research on Relaxin in Cardiovascular and Other
Diseases, Prosperius Institute, Florence, Italy), The bicinchoninic acid
Protein Assay kit and SuperBlock blocking buffer were from Pierce
Biotechnology Inc. (Rockford, IL, USA). Antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Luminol ECL was from
Amersham (Buckinghamshire, United Kingdom).
Table 1 Histopathological scoring criteria
Grade Glomeruli Proximal/distal tubuli Blood vessels
0 Normal Normal Normal
1 Microvacuolation Microvacuolation Focal dilation and blood stasis
2 Vacuolation Vacuolation, ruffled border disappearance,
cell shedding, rare casts
Diffuse dilation and blood stasis
3 Vacuolation, cell shedding,
enlargement of Bowman capsule
Vacuolation, diffuse cell detachment, many casts Diffuse, severe dilation and blood stasis,
interstitial haemorrhage
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Statistical analysis
All values in both the text and figures are expressed as mean  SEM
for n observations. One-way ANOVA with Dunnett’s post-test was per-
formed with the GraphPad Prism Software (San Diego, CA, USA) and P
values below 0.05 were considered significant.
Results
Effect of acute rhRLX administration on
I/R-induced renal dysfunction
Rats that underwent renal I/R exhibited a significant increase in
serum levels of urea and creatinine, compared with sham-operated
rats (Fig. 1A and B respectively). To discount the possibility of a
rapid increase in serum creatinine levels because of increased
release of creatinine from muscle during I/R, creatinine clearance
was also measured. Ischaemia/reperfusion exposure led to a dras-
tic decrease in creatinine clearance (Fig. 1C) as well as in urine
flow (Fig. 1D). Interestingly, administration of rhRLX during reper-
fusion prevented the increase in the serum concentrations of urea
and creatinine and resulted in a significant increase in creatinine
clearance and urine flow (Fig. 1A–D), thus indicating improvement
in renal injury and glomerular dysfunction. Renal I/R evoked a sig-
nificant increase in urinary NAG levels, suggesting significant tubu-
lar dysfunction, which was markedly reduced by rhRLX
administration (Fig. 1E). Conversely, the administration of rhRLX to






Fig. 1 Effect of I/R and rhRLX on renal dysfunction evaluated on
blood and urine parameters. Serum creatinine (A), urea (B), creati-
nine clearance (C), urine flow (D) and urinary N-acetyl-b-glucosa-
minidase levels (E) were measured after sham operation (Sham) or
renal ischaemia–reperfusion injury (IR). Further groups of rats
received rhRLX (5 lg/kg, i.v.) at the beginning of reperfusion and
again after 3 hrs of reperfusion (Sham+RLX and IR+RLX). Data are
expressed as mean  SEM. ★P < 0.05 versus IR.
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Effects of rhRLX on the histological signs of
injury caused by I/R
Figure 2 depicts representative histopathological features of the kid-
ney (cortex and medulla) from rats belonging to the different experi-
mental groups. When compared with the normal kidney morphology
of the sham-operated rats, the samples taken from the animals
undergoing renal I/R showed typical features of glomerular, tubular
and vascular injury. In particular, large tissue areas in both the renal
cortex and medulla showed widespread tubular cell vacuolization with
reduced or absent ruffled border, accompanied by focal necrosis,
shedding of the tubular epithelial lining and formation of hyaline tubu-
lar casts. The interstitial connective tissue showed very dilated micro-
vessels filled with blood (peliosis) and sparse haemorrhage foci.
Glomeruli in the renal cortex also showed cell microvacuolation and
occasional blood extravasation in the Bowman capsule. Of note,
rhRLX administration at reperfusion markedly reduced these renal
abnormalities, the most evident changes being tubular cell microvac-
uolation and a moderate degree of microvascular dilation. Semi-quan-
titative scoring of kidney injury performed on the histological slides
confirmed the visual observations and showed that rhRLX signifi-
cantly attenuates renal cell damage (Fig. 2).
Effects of rhRLX on oxidative stress induced by
renal I/R injury
Rats that had undergone I/R exhibited a massive increase in tissue
markers of oxidative stress, such as TBARS production, an index of
peroxidation of cell membrane lipids, and 8-OHdG, a marker of free
radical-induced DNA damage (Fig. 3A and B, respectively). The
robust increase in TBARS and 8-OHdG levels was blunted by rhRLX
administration. Renal I/R injury evoked a significant decrease in the
activity of the endogenous antioxidant enzymes MnSOD and CuZn-
SOD (Fig. 4A and B, respectively), which was associated with a slight
suppression of their protein expression (Fig. 4C and D). Interestingly,
rhRLX administration almost completely abolished the I/R-induced
reduction in MnSOD and CuZnSOD activities and evoked a massive
protein up-regulation, above the control levels. On the other hand,
rhRLX administration to sham-operated animals had no significant
effect on any of the measured markers.
Effects of rhRLX on inflammatory markers
The improvement in the outcome of I/R injury was associated with a
marked modulation of the leucocyte accumulation measured in kidney
samples at term of reperfusion. As shown in Figure 5A, renal I/R
caused a robust increase in MPO activity, a specific leucocyte marker,
in comparison with sham-operated rats. In the animals treated with
rhRLX during reperfusion, the MPO activity was significantly reduced.
The adhesion molecule ICAM-1, which is the endothelial ligand for the
neutrophil receptor CD11b/CD18, was barely detectable in the kidney
from sham-operated animals, while its expression was strongly
induced by I/R (Fig. 5B). Administration of rhRLX drastically reduced
the I/R-induced increase in ICAM-1 expression.
Interleukin-1b, IL-18 and TNF-a, typical pro-inflammatory cyto-
kines, were significantly increased in renal tissue of ischaemic/reper-
fused rats, as compared with the sham-operated animals (Fig. 6A–C
respectively). Interestingly, administration of rhRLX prevented the I/
R-induced rise in IL-1b, IL-18 and TNF-a, levels. When the plasmatic
content of the well-known anti-inflammatory cytokine IL-10 was mea-
sured (Fig. 6D), a slight decrease in its serum level was detectable in
the rats that underwent I/R injury, whereas rhRLX administration
reported IL-10 concentration back to values similar to those mea-
sured in sham-operated animals.
Effect of rhRLX on ERK1/2 phosphorylation and
iNOS expression in the kidneys of rats that
underwent I/R injury
To gain a better insight into the potential mechanism(s) underlying the
observed beneficial effects of rhRLX, we investigated the effects of this
hormone on cell signalling pathways known to confer protection to the
kidney and that have been previously demonstrated to mediate rhRLX
effects in other organs. The phosphorylation of ERK1/2 MAPK was not
significantly affected by I/R injury; however, when ischaemic/reper-
fused rats were treated with rhRLX, we detected a massive increase in
ERK phosphorylation (Fig. 7A). As shown in Figure 7B, densitometric
analysis of the Western blot bands detected low iNOS protein levels in
the kidney obtained from sham-operated animals. I/R injury induced a
slight increase in the expression of iNOS, which was maximum in the
group of animals treated with rhRLX during reperfusion.
Effect of rhRLX on the phosphorylation of Akt
and eNOS in the kidneys of rats that underwent
I/R injury
When compared with sham-operated rats, rats that underwent I/R
injury developed significant decreases in the phosphorylation of Akt on
Ser473 in reperfused kidney samples (Fig. 8A). Therapeutic administra-
tion of rhRLX during reperfusion attenuated the decline in Akt phos-
phorylation caused by I/R. The degree of the phosphorylation of eNOS
on Ser1177 was similar in sham-operated rats and ischaemic/reper-
fused rats indicating that I/R alone is not sufficient to affect eNOS phos-
phorylation (Fig. 8B). Treatment of ischaemic/reperfused rats with
rhRLX resulted in a twofold increase in the phosphorylation of eNOS
when compared with rats exposed to I/R only.
Discussion
Although recent preclinical and clinical studies have demonstrated
that RLX may have important therapeutic potential in chronic kid-
ney diseases, such as renal fibrosis and salt-sensitive hypertension
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[26], its role in AKI has never been elucidated The present findings
offer first experimental evidence that the therapeutic administration
of rhRLX at reperfusion significantly reduces renal injury and dys-
function caused by I/R in rats, while it has no effect on normal
renal function in sham-operated animals. The dose of rhRLX used
in this study has been previously reported to protect other organs
against I/R injury and to prevent the development of acute pancrea-
titis [3, 27, 28]. Notably, to simulate the clinical conditions, in our
experimental model, rhRLX was only applied during reperfusion,
indicating that this treatment strategy could be potentially employed
in several situations known to result in AKI, including renal trans-
plantation, aortic aneurysm surgery, or X-ray contrast tracer-
induced nephropathy, to protect or even rescue a kidney previously
challenged by ischaemia. Our results further corroborate and
extend the previous findings demonstrating that RLX is capable of
ameliorating renal hemodynamics by inducing selective renal vaso-
dilation and hyperfiltration in both rats and humans [29, 30]. In
our experimental model, the improvements in the outcome of renal
Fig. 2 Representative histopathological features of kidney
biopsies in the different experimental groups and semi-
quantitative assessment of the severity of kidney damage.
Upper panels: widespread tubular cell vacuolization, shed-
ding of the tubular epithelial lining (arrowheads) and hya-
line tubular casts (asterisks) are seen in the renal cortex
and medulla; the interstitial connective tissue shows
dilated microvessels filled with blood and sparse haemor-
rhage foci. Below panel: severity scoring of the histologi-
cal damage. Significance of differences: ★★P < 0.01 and
★★★P < 0.001 versus IR.
ª 2013 The Authors.
Journal of Cellular and Molecular Medicine Published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
1499
J. Cell. Mol. Med. Vol 17, No 11, 2013
A B
Fig. 3 Effects of I/R and rhRLX on lipid peroxidation and free radical-induced DNA in kidney samples. TBARS production (A), 8-OHdG levels (B)
were measured subsequent to sham operation (Sham) or renal ischaemia–reperfusion injury (IR) in the absence (vehicle) or presence of rhRLX
(5 lg/kg, i.v.; Sham+RLX and IR+RLX). Data are expressed as mean  SEM. ★P < 0.05 versus IR.
A B
C D
Fig. 4 Effects of I/R and rhRLX on activity and expression of manganese-superoxide dismutases (MnSOD) and copper-zinc-superoxide dismutases
(CuZnSOD) in kidney samples. Activity (A and B) and protein expression (C and D) of the SOD isoforms mitochondrial MnSOD and cytosolic CuZn-
SOD were measured in kidney homogenates of sham-operated rats (Sham) and rats that underwent 1-hr ischaemia and 6-hr reperfusion (IR) in the
absence or presence of rhRLX (5 lg/kg, i.v.; Sham+RLX and IR+RLX). Each immunoblot is from a single experiment and is representative of three
separate experiments. Densitometric analysis of the bands is expressed as relative optical density (O.D.), corrected for the corresponding b-actin
contents and normalized using the related sham-operated band. Data are means  SEM of three separate experiments for Western Blot and five
animals/group for SOD activity. ★P < 0.05 versus IR.
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Fig. 5 Effects of I/R and rhRLX on leucocyte accumulation in kidney samples. Myeloperoxidase (MPO) activity (A) and ICAM-1 expression (B) were
measured in kidney homogenates of sham-operated rats (Sham) and rats that underwent 1-hr ischaemia and 6-hr reperfusion (IR) in the absence or
presence of rhRLX (5 lg/kg, i.v.; Sham+RLX and IR+RLX). Each immunoblot is from a single experiment and is representative of three separate
experiments. Densitometric analysis of the bands is expressed as relative optical density (O.D.), corrected for the corresponding b-actin contents and
normalized using the related sham-operated band. Data are means  SEM of three separate experiments for Western Blot and five animals/group for
MPO. ★P < 0.05 versus IR.
A B
C D
Fig. 6 Effects of I/R and rhRLX on cytokine production in kidney samples. IL-1b (A), IL-18 (B), TNF-a (C) and IL-10 (D) levels were measured in
the kidney of sham-operated rats (Sham) and rats that underwent 1-hr ischaemia and 6-hr reperfusion (IR) in the absence or presence of rhRLX
(5 lg/kg, i.v.; Sham+RLX and IR+RLX). Data are means  SEM of five animals/group. ★P < 0.05 versus IR.
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damage by rhRLX administration were associated with a significant
inhibition of both the inflammatory response and oxidative stress
induced by I/R. Namely, rhRLX reduced leucocyte adhesion to is-
chaemic-reperfused vascular endothelium, as suggested by its abil-
ity to suppress the expression of the adhesion molecule ICAM-1
and the activity of MPO, selected as typical markers of leucocyte
inflammatory recruitment, which were both drastically up-regulated
by I/R. At the same time, rhRLX significantly decreased the produc-
tion of TNF-a, IL-1b and IL-18 in the kidney of animals that under-
went I/R injury. Interestingly, this effect was associated with
increased level of the anti-inflammatory cytokine IL-10, suggesting
that RLX may operate a shift from a pro-inflammatory to an anti-
inflammatory status. These results are consistent with previous
reports demonstrating the role of RLX as a potent inhibitory factor
in early vascular inflammation with prominent inhibitory effects on
the expression of cytokines and adhesion molecules [31–33]. The
attenuated inflammatory response caused by rhRLX treatment may
also account for the decrease in tissue markers of oxidative stress,
thus supporting the notion that release of ROS from activated leu-
cocytes provides a major contribution to peroxidation of lipid mem-
branes and free radical-induced DNA damage in the kidney.
Besides, a direct effect of RLX on oxidative stress has also been
recently demonstrated by Dschietzig et al. [34], showing that RLX
stimulates CuZnSOD expression in rat aortic rings, by increasing
the CuZnSOD promoter activity at different time-points. Our find-
A
B
Fig. 8 Effects of I/R and rhRLX on Akt and eNOS phosphorylation. Rep-
resentative Western blot and corresponding densitometric analysis of
the bands showing phosphorylated (Ser473) and total Akt (A) and phos-
phorylated (Ser1177) and total eNOS in the presence or absence of
rhRLX (5 lg/kg, i.v.; Sham+RLX and IR+RLX). Each immunoblot is
from a single experiment and is representative of three separate experi-
ments. Densitometric analysis of the related bands is expressed as rela-
tive optical density, corrected for the corresponding b-actin contents,
and normalized using the related sham-operated band. The data from
bands densitometric analysis are means  SEM of three separate
experiments. ★P < 0.05 versus IR.
A
B
Fig. 7 Effects of I/R and rhRLX on ERK phosphorylation and iNOS
expression. Representative Western blot and corresponding densitomet-
ric analysis of the bands showing phosphorylated (Thr202/Tyr204) and
total ERK1/2 MAPK (A) and iNOS (B) protein expression after 6 hrs of
reperfusion in the presence or absence of rhRLX (5 lg/kg, i.v.;
Sham+RLX and IR+RLX). Each immunoblot is from a single experiment
and is representative of three separate experiments. Densitometric analy-
sis of the related bands is expressed as relative optical density, cor-
rected for the corresponding b-actin contents, and normalized using the
related sham-operated band. The data from bands densitometric analysis
are means  SEM of three separate experiments. ★P < 0.05 versus IR.
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ings are in keeping with previous studies from our and other
research groups showing that RLX exerts beneficial effects against
organ ischaemic damage by reducing local leucocyte recruitment
and oxidative stress [3, 4, 6]. Accordingly, RLX has also been pro-
posed as a protective substance in preservation solutions for lung
and liver transplantation [5, 35, 36]. Despite these intriguing data
and the evidence that the kidney is the organ of greatest uptake of
exogenously administered RLX [19], the specific signal transduction
pathway by which RLX exerts its effects in the kidney remains to
be fully elucidated. Previous studies have demonstrated that several
renal biological actions of RLX, including its potent antifibrotic
effects, are mediated by functional activation of the relaxin receptor
RXFP1, which is expressed by specific renal cells, such as mesan-
gial cells and myofibroblasts [37, 38]. RXFP1 signalling is complex,
involving multiple pathways depending on the cell type under inves-
tigation; however, recent evidence suggests a key role for the nitric
oxide pathway in mediating major renovascular effects of RLX [39].
For instance, Sasser et al. [40] have demonstrated that RLX was
ineffective in preventing chronic renal injury during administration
of the nitric oxide synthase inhibitor N(x)-nitro-l-arginine methyl
ester (L-NAME), suggesting that the renoprotective effects of RLX
are dependent on a functional NOS system. Although the exact sig-
nalling mechanisms of RXFP1 were beyond the scope of this study,
we could demonstrate an involvement of the nitric oxide pathway
in the RLX-mediated effects reported here: in fact, RLX administra-
tion was associated with eNOS activation and induction of iNOS
expression, resulting in enhanced formation of nitric oxide in the
microcirculation. In conditions associated with I/R, the enhanced
formation of nitric oxide is beneficial, as it can cause local vasodi-
lation, inhibit adhesion of platelets and leucocytes and promote
angiogenesis [41]. There is good evidence that agents that release
nitric oxide or enhance the formation of endogenous nitric oxide
attenuate organ injury/dysfunction in AKI [42, 43]. By a nitric
oxide-dependent mechanism, RLX has been shown to strongly inhi-
bit neutrophil activation, thereby reducing free radical generation,
chemotaxis and platelet aggregation [44, 45]. Therefore, the
reduced oxidative stress status and leucocyte activation here
reported may be explained, at least in part, by the ability of RLX to
up-regulate the NOS/nitric oxide pathway. Previous studies in cul-
tured human endothelial cells have shown that RLX can evoke
eNOS activation by phosphorylation of specific serine residues in
Akt [46]. Akt is a member of the phosphoinositide 3-kinase signal
transduction enzyme family which, upon phosphorylation by its
upstream regulator, can modulate inflammatory responses and
apoptosis [47]. A reduction in the activation of this important sur-
vival pathway has been recently demonstrated to make the kidney
more susceptible to I/R insult [48, 49]. Here, we show that RLX
caused a robust increase in Akt phosphorylation. This indicates a
significant Akt activation, which in turn could promote eNOS phos-
phorylation and renal protection. An additional contribution to the
regulatory effects of RLX on nitric oxide pathway may rely on its
ability to affect ERK1/2 MAPK pathway, which is another important
signal for cell survival [50]. ERK activation protects renal epithelial
cells from oxidative injury [51] and, particularly relevant to this
study, it leads to iNOS induction in renal epithelial cells [52], renal
myofibrobalsts [53], vascular smooth muscle cells [54] and murine
macrophages [55]. As we documented increased ERK1/2 activation
in the presence of RLX, we propose that MAPK activation by RLX
is, at least in part, responsible for the RLX-mediated modulation of
iNOS expression. However, it must be underlined that ERK1/2 and
Akt activation by RLX was recorded at 6 hrs after reperfusion. As
RLX has a short serum half-life in rodents [19], we cannot rule out
the possibility that RLX evokes an early intracellular signalling cas-
cade leading to late ERK and Akt activation, thus resulting in
increased NOS activity/expression.
In conclusion, this study provides first experimental evidence that
acute RLX administration during reperfusion attenuates the renal dys-
function and injury caused by I/R in the rat and that these renoprotec-
tive effects of RLX involve the activation of eNOS and up-regulation of
iNOS, possibly secondary to activation of Akt and ERK1/2, respec-
tively. The modulation of the nitric oxide pathway appears a crucial
mechanism through which RLX selectively inhibits the inflammatory
response and oxidative stress sparkled by renal I/R. Overall, these
findings provide further evidence to the concept that RLX may be
regarded as a therapeutic tool in diseases characterized pathogenical-
ly by vascular dysfunction and impaired nitric oxide production.
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